Top 10 States for Physician-Owned Hospitals - Summary - MDSpire

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

  • By

  • Conexiant News Staff

  • May 1, 2026

  • 3 min

Share

Objective:

To outline the regulatory environment for physician-owned hospitals across various states in the U.S.

Key Findings:
  • Physician ownership is regulated by both federal and state laws.
  • Each state has specific statutes governing the practice of medicine and physician licensure, which can impact ownership opportunities.
  • Population demographics and growth rates vary significantly across states, influencing the regulatory environment.
Interpretation:

The regulatory landscape for physician-owned hospitals is complex and varies by state, impacting physician participation and ownership opportunities.

Limitations:
  • The article does not provide detailed comparisons of the regulatory frameworks across states.
  • Population data may not reflect current trends post-2020.
  • Lack of detailed state comparisons limits understanding of the regulatory landscape.
Conclusion:

Understanding both federal and state-specific regulations is crucial for physicians considering ownership of hospitals.

Sources:

Original Source(s)

Top 10 States for Physician-Owned Hospitals

  • by Conexiant News Staff

  • May 1, 2026

Related Content

Cancer Screening Gaps Seen in Sexual, Gender Minority Groups

A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.

Does Pediatric Readiness Reduce ED Imaging?

Hospitals with stronger pediatric emergency capability used less imaging overall, but differences by insurance status and race and ethnicity remained.

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.